Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

71.75CHF
17 May 2013
Price Change (% chg)

CHF-0.45 (-0.62%)
Prev Close
CHF72.20
Open
CHF71.95
Day's High
CHF72.15
Day's Low
CHF71.45
Volume
4,614,130
Avg. Vol
5,047,086
52-wk High
CHF73.25
52-wk Low
CHF48.29

NOVN.VX

Chart for NOVN.VX

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.75
Market Cap (Mil.): CHF195,719.30
Shares Outstanding (Mil.): 2,706.19
Dividend: 2.30
Yield (%): 3.19

Financials

  NOVN.VX Industry Sector
P/E (TTM): 19.13 35.66 35.83
EPS (TTM): 3.78 -- --
ROI: 10.42 19.36 18.72
ROE: 14.75 20.07 19.54
Search Stocks

Novartis, BT push European shares to fresh 5-yr peak

LONDON, May 10 - European shares scaled fresh five-year highs on Friday, led by healthcare group Novartis and telecoms firm BT on positive corporate news, and traders said key indexes had scope for more gains.

10 May 2013

U.S. approves Novartis drug Ilaris to treat childhood arthritis

ZURICH, May 10 - Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.

10 May 2013

U.S. sues Novartis over kickbacks

NEW YORK - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

26 Apr 2013

U.S. sues Novartis over kickbacks, second case this week

NEW YORK - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

26 Apr 2013

UPDATE 2-U.S. sues Novartis over kickbacks, 2nd case this week

NEW YORK, April 26 - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

26 Apr 2013

U.S. files 2nd lawsuit accusing Novartis of kickbacks

April 26 - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multi-million dollar kickbacks to doctors in exchange for prescribing its drugs.

26 Apr 2013

BRIEF-U.S. joins whistleblower lawsuit against Novartis over alleged kickbacks

April 26 - Novartis AG : * U.S. says joins whistleblower lawsuit against Novartis AG over

26 Apr 2013

UPDATE 2-Novartis names new finance chief to boost productivity

* Reports earnings per share of $1.32 vs estimates for $1.30

24 Apr 2013

BRIEF-Novartis to cut 300 jobs at consumer health unit

ZURICH, April 24 - Novartis AG : * Says will cut some 300 positions at consumer health unit, as downsizes

24 Apr 2013

Novartis names Harry Kirsch new CFO

ZURICH, April 24 - Swiss drugmaker Novartis named Harry Kirsch as new Chief Financial Officer to help improve productivity as the Basel-based drugmaker looks to grow beyond a wave of patent expiries.

24 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$127.00
Provider: ValuEngine, Inc.
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks